Page last updated: 2024-12-05
n,n,n',n'-tetramethylbenzidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9702 |
| CHEMBL ID | 3823639 |
| SCHEMBL ID | 124209 |
| MeSH ID | M0074273 |
Synonyms (44)
| Synonym |
|---|
| [1,1'-biphenyl]-4,4'-diamine, n,n,n',n'-tetramethyl- |
| benzidine, n,n,n',n'-tetramethyl- |
| n,n,n',n'-tetramethylbenzidine |
| nsc 433 |
| 4,4'-bis(n,n-dimethylamino)biphenyl |
| (1,1'-biphenyl)-4,4'-diamine, n,n,n',n'-tetramethyl- |
| n,n,n',n'-tetramethyl-(1,1'-biphenyl)-4,4'-diamine |
| einecs 206-676-5 |
| ccris 1000 |
| ai3-61957 |
| n,n,n',n'-tetramethyl-p,p'-benzidine |
| CHEMDIV2_000092 , |
| benzidine,n,n',n'-tetramethyl- |
| nsc-433 |
| nsc433 |
| [1,4'-diamine, n,n,n',n'-tetramethyl- |
| 366-29-0 |
| n,n',n'-tetramethylbenzidine |
| n,n,n',n'-tetramethylbenzidine, >=95% (hplc) |
| AKOS001482346 |
| HMS1369E04 |
| T0141 |
| 4,4'-bis(dimethylamino)biphenyl |
| n-[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]-n,n-dimethylamine |
| (1,1'-biphenyl)-4,4'-diamine, n4,n4,n4',n4'-tetramethyl- |
| CCG-103298 |
| FT-0632049 |
| AB01331573-02 |
| SCHEMBL124209 |
| [1,1'-biphenyl]-4,4'-diamine,n,n,n'',n'-tetramethyl- |
| n4,n4,n4',n4'-tetramethyl-[1,1'-biphenyl]-4,4'-diamine |
| CHEMBL3823639 |
| DTXSID0036845 |
| SR-01000390721-1 |
| sr-01000390721 |
| mfcd00008310 |
| n,n,n,n-tetramethylbenzidine |
| 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline |
| n4,n4,n4',n4'-tetramethylbiphenyl-4,4'-diamine |
| AMY33203 |
| D92306 |
| NCGC00338604-01 |
| BS-23690 |
| CS-0044367 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1310986 | Inhibition of ATGL in mouse 3T3L1 cells assessed as inhibition of isoproterenol-stimulated lipolysis by measuring reduction in glycerol release in media at 20 uM preincubated for 4 hrs followed by isoproterenol addition measured after 1 hr by colorimetric | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | New Atglistatin closely related analogues: Synthesis and structure-activity relationship towards adipose triglyceride lipase inhibition. |
| AID1310985 | Inhibition of ATGL in mouse 3T3L1 cells assessed as inhibition of isoproterenol-stimulated lipolysis by measuring reduction in non-esterified fatty acid release in media at 20 uM preincubated for 4 hrs followed by isoproterenol addition measured after 1 h | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | New Atglistatin closely related analogues: Synthesis and structure-activity relationship towards adipose triglyceride lipase inhibition. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (16)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (43.75) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.40
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.40) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||